eflornithine/sulindac (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Familial Adenomatous Polyposis

Pending FDA approval to delay the need for major surgeries in the colon, rectum or surgical pouch owing to familial adenomatous polyposis (FAP)

Next:

Pharmacology

Mechanism of Action

Eflornithine: Irreversibly inhibits ornithine decarboxylase (ODC), an enzyme that catalyzes biosynthesis of intracellular polyamines required for cell division and differentiation

Sulindac: Nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.